Stay updated with breaking news from Teneoone inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments Amgen and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments … Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity hol ....
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.